Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates

Cytokinetics, Incorporated (NASDAQ:CYTK) is rolling out MYQORZO for obstructive HCM with accelerating uptake (~2.5—3k patient starts, scripts up to ~1,500) while advancing omecamtiv and ulacamten trials, backed by partnerships and a Vision 2030 plan to expand therapies, indications and reach.Previo…